Litigation Innovation: Article One Partners Seeks Art To Invalidate Patents
Brand-name drug manufacturers have a new nemesis in their patent wars: Article One Partners. The group is gathering data to challenge the validity of high-profile patents in litigation
You may also be interested in...
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
Enrollment-boosting strategy backed by industry rep at Duke-Margolis meeting as FDA official suggests having sponsors develop study plans for pregnant and lactating women with ‘elements of’ the requirement for pediatric studies.